Table 2.
Summary of clinical efficacy results evaluating anlotinib in patients with cancer
| Cancer type | Phase | Number of patients | ORR, % (anlotinib group). | ORR, % (control group). | PFS (median, months, anlotinib group). | PFS (median, months, control group). | OS (median, months, anlotinib group). | OS (median, months, control group). | Author | Ref |
|---|---|---|---|---|---|---|---|---|---|---|
| Advanced NSCLC | II (randomized control) | 117 | 10.0 | 0.00 | 4.8 | 1.2 | 9.30 | 6.30 | Han B | [25] |
| Advanced NSCLC | III | 437 | 9.18 | 0.7 | 5.37 | 1.40 | 9.63 | 6.30 | Han B | [26] |
| Advanced STS | II (single-arm) | 166 | 11.45 | / | 5.63 | / | NA | / | Chi Y | [42] |
| Advanced STS | IIB (randomized control) | 233 | 10.13 | 1.33 | 6.27 | 1.47 | NA | NA | Chi Y | [44] |
| mRCC | II (single-arm) | 43 | 19.1 | / | 11.8 (whole group);8.5(progressed on a TKI group) | / | NA | NA | Zhou A P | [50] |
| mRCC | II (randomized control) | 133 | 24.4 | 23.3 | 11.3 | 11.0 | NA | NA | Zhou AP | [51] |
| Advanced MTC | II (single-arm) | 58 | 48.28 | / | 12.8 | / | NA | / | Sun Y | [57] |
NSCLC non-small-cell lung cancer, ORR overall response rate, PFS progression-free survival, OS overall survival, NA data not available, STS soft tissues sarcoma, mRCC metastatic renal cell carcinoma, TKI tyrosine kinase inhibitor, MTC medullary thyroid cancer